Background: Due to the excellent physical and biochemical characteristics of 68 Ga, 68 Ga-1,4,7-triazacy-clononane-glutaric acid-4,7 acetic acid-arginyl-glycyl-aspartic acid-bombesin ( 68 Ga-NODAGA-RGD-BBN) was prepared as a new positron emission tomography (PET) imaging agent, and afterward, the preclinical evaluation of this labeled peptide was studied.Materials and Methods: 68 Ga radioisotope was extracted from a 68 Ge/ 68 Ga generator with high radionuclide, chemical and radiochemical purities.Then; the 68 Ga-NODAGA-RGD-BBN radiolabeled complex was prepared at optimized conditions.The stability of the complex was evaluated in phosphatebuffered saline (PBS) for at least 2 h.Cell studies of the radiolabeled peptide were also assessed on the gastrin releasing peptide receptor (GRPR)-expressing cell line.Finally; the biodistribution and whole-body scan imaging study of 68 Ga-NODAGA-RGD-BBN was studied in normal and tumor-bearing mice.Results: The biodistribution and whole -body scan imaging of the radiolabeled compound on GRPR-expressing tumor-bearing mice demonstrated the high uptake in the tumor site at all post-injection intervals.The biodistribution results also demonstrated the major excretion route of the complex is the urinary tract.Conclusions: 68 Ga-NODAGA-RGD-BBN shows high potential for PET imaging of patients with GRPR-expressing tumors; however, more biological studies are still needed.